Loading…
Biphasic modulation of insulin receptor substrate-1 during goitrogenesis
Insulin receptor substrate-1 (IRS-1) is the main intracellular substrate for both insulin and insulin-like growth factor I (IGF-I) receptors and is critical for cell mitogenesis. Thyrotropin is able to induce thyroid cell proliferation through the cyclic AMP intracellular cascade; however, the prese...
Saved in:
Published in: | Brazilian journal of medical and biological research 2007-05, Vol.40 (5), p.679-686 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 686 |
container_issue | 5 |
container_start_page | 679 |
container_title | Brazilian journal of medical and biological research |
container_volume | 40 |
creator | Grozovsky, R. Morales, M.M. Carvalho, D.P. |
description | Insulin receptor substrate-1 (IRS-1) is the main intracellular substrate for both insulin and insulin-like growth factor I (IGF-I) receptors and is critical for cell mitogenesis. Thyrotropin is able to induce thyroid cell proliferation through the cyclic AMP intracellular cascade; however, the presence of either insulin or IGF-I is required for the mitogenic effect of thyroid-stimulating hormone (TSH) to occur. The aim of the present study was to determine whether thyroid IRS-1 content is modulated by TSH in vivo. Strikingly, hypothyroid goitrous rats, which have chronically high serum TSH levels (control, C = 2.31 ± 0.28; methimazole (MMI) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated with 0.03% MMI in drinking water for 21 days, showed significantly reduced thyroid IRS-1 mRNA content. Since goiter was already established in these animals by MMI for 21 days, we also evaluated IRS-1 expression during goitrogenesis. Animals treated with MMI for different periods of time showed a progressive increase in thyroid weight (C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MMI 10d = 33.8 ± 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.9 ± 3.92 mg, N = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; MMI 5d = 9.95 ± 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25.65 ± 1.23; MMI 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals per group). Thyroid IRS-1 mRNA expression increased progressively during goitrogenesis, being significantly higher by the 14th day of MMI treatment, and then started to decline, reaching the lowest values by the 21st day, when a significant reduction was detected. In the liver of these animals, however, a significant decrease of IRS-1 mRNA was detected after 14 days of MMI treatment, a mechanism probably involved in the insulin resistance that occurs in hypothyroidism. The increase in IRS-1 expression during goitrogenesis may represent an important event associated with the increased rate of cell mitosis promoted by TSH and indicates that insulin and IGF-I are important co-mitogenic factors in vivo, possibly acting through the activation of IRS-1. |
doi_str_mv | 10.1590/S0100-879X2006005000090 |
format | article |
fullrecord | <record><control><sourceid>scielo</sourceid><recordid>TN_cdi_scielo_journals_S0100_879X2007000500011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S0100_879X2007000500011</scielo_id><sourcerecordid>S0100_879X2007000500011</sourcerecordid><originalsourceid>FETCH-LOGICAL-s243t-cb086b93b2159e12a3d4be2d74631a79bb30bb908388975a63bea4fbe06d50a03</originalsourceid><addsrcrecordid>eNotj81OAyEUhVloYq0-g7wA9V5gflhqo9akiQs16W4CAzPSjNAA8_5ObM_m7M53PkIeEDZYKXj8BARgbaMOHKAGqGCJgiuyQomSSYGHG3Kb8xGAVyBxRXbP_vSjs-_pb7TzpIuPgcaB-pDnyQeaXO9OJSaaZ5NL0sUxpHZOPox0jL6kOLrgss935HrQU3b3l16T79eXr-2O7T_e3rdPe5a5FIX1BtraKGH4ctgh18JK47htZC1QN8oYAcYoaEXbqqbStTBOy8E4qG0FGsSabM67ufduit0xzikswO7fvbu4N3CWRxR_QmxQgg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Biphasic modulation of insulin receptor substrate-1 during goitrogenesis</title><source>IngentaConnect Journals</source><source>SciELO</source><creator>Grozovsky, R. ; Morales, M.M. ; Carvalho, D.P.</creator><creatorcontrib>Grozovsky, R. ; Morales, M.M. ; Carvalho, D.P.</creatorcontrib><description>Insulin receptor substrate-1 (IRS-1) is the main intracellular substrate for both insulin and insulin-like growth factor I (IGF-I) receptors and is critical for cell mitogenesis. Thyrotropin is able to induce thyroid cell proliferation through the cyclic AMP intracellular cascade; however, the presence of either insulin or IGF-I is required for the mitogenic effect of thyroid-stimulating hormone (TSH) to occur. The aim of the present study was to determine whether thyroid IRS-1 content is modulated by TSH in vivo. Strikingly, hypothyroid goitrous rats, which have chronically high serum TSH levels (control, C = 2.31 ± 0.28; methimazole (MMI) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated with 0.03% MMI in drinking water for 21 days, showed significantly reduced thyroid IRS-1 mRNA content. Since goiter was already established in these animals by MMI for 21 days, we also evaluated IRS-1 expression during goitrogenesis. Animals treated with MMI for different periods of time showed a progressive increase in thyroid weight (C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MMI 10d = 33.8 ± 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.9 ± 3.92 mg, N = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; MMI 5d = 9.95 ± 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25.65 ± 1.23; MMI 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals per group). Thyroid IRS-1 mRNA expression increased progressively during goitrogenesis, being significantly higher by the 14th day of MMI treatment, and then started to decline, reaching the lowest values by the 21st day, when a significant reduction was detected. In the liver of these animals, however, a significant decrease of IRS-1 mRNA was detected after 14 days of MMI treatment, a mechanism probably involved in the insulin resistance that occurs in hypothyroidism. The increase in IRS-1 expression during goitrogenesis may represent an important event associated with the increased rate of cell mitosis promoted by TSH and indicates that insulin and IGF-I are important co-mitogenic factors in vivo, possibly acting through the activation of IRS-1.</description><identifier>ISSN: 1414-431X</identifier><identifier>DOI: 10.1590/S0100-879X2006005000090</identifier><language>eng</language><publisher>Associação Brasileira de Divulgação Científica</publisher><subject>BIOLOGY ; MEDICINE, RESEARCH & EXPERIMENTAL</subject><ispartof>Brazilian journal of medical and biological research, 2007-05, Vol.40 (5), p.679-686</ispartof><rights>This work is licensed under a Creative Commons Attribution 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,24150,27924,27925</link.rule.ids></links><search><creatorcontrib>Grozovsky, R.</creatorcontrib><creatorcontrib>Morales, M.M.</creatorcontrib><creatorcontrib>Carvalho, D.P.</creatorcontrib><title>Biphasic modulation of insulin receptor substrate-1 during goitrogenesis</title><title>Brazilian journal of medical and biological research</title><addtitle>Braz J Med Biol Res</addtitle><description>Insulin receptor substrate-1 (IRS-1) is the main intracellular substrate for both insulin and insulin-like growth factor I (IGF-I) receptors and is critical for cell mitogenesis. Thyrotropin is able to induce thyroid cell proliferation through the cyclic AMP intracellular cascade; however, the presence of either insulin or IGF-I is required for the mitogenic effect of thyroid-stimulating hormone (TSH) to occur. The aim of the present study was to determine whether thyroid IRS-1 content is modulated by TSH in vivo. Strikingly, hypothyroid goitrous rats, which have chronically high serum TSH levels (control, C = 2.31 ± 0.28; methimazole (MMI) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated with 0.03% MMI in drinking water for 21 days, showed significantly reduced thyroid IRS-1 mRNA content. Since goiter was already established in these animals by MMI for 21 days, we also evaluated IRS-1 expression during goitrogenesis. Animals treated with MMI for different periods of time showed a progressive increase in thyroid weight (C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MMI 10d = 33.8 ± 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.9 ± 3.92 mg, N = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; MMI 5d = 9.95 ± 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25.65 ± 1.23; MMI 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals per group). Thyroid IRS-1 mRNA expression increased progressively during goitrogenesis, being significantly higher by the 14th day of MMI treatment, and then started to decline, reaching the lowest values by the 21st day, when a significant reduction was detected. In the liver of these animals, however, a significant decrease of IRS-1 mRNA was detected after 14 days of MMI treatment, a mechanism probably involved in the insulin resistance that occurs in hypothyroidism. The increase in IRS-1 expression during goitrogenesis may represent an important event associated with the increased rate of cell mitosis promoted by TSH and indicates that insulin and IGF-I are important co-mitogenic factors in vivo, possibly acting through the activation of IRS-1.</description><subject>BIOLOGY</subject><subject>MEDICINE, RESEARCH & EXPERIMENTAL</subject><issn>1414-431X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNotj81OAyEUhVloYq0-g7wA9V5gflhqo9akiQs16W4CAzPSjNAA8_5ObM_m7M53PkIeEDZYKXj8BARgbaMOHKAGqGCJgiuyQomSSYGHG3Kb8xGAVyBxRXbP_vSjs-_pb7TzpIuPgcaB-pDnyQeaXO9OJSaaZ5NL0sUxpHZOPox0jL6kOLrgss935HrQU3b3l16T79eXr-2O7T_e3rdPe5a5FIX1BtraKGH4ctgh18JK47htZC1QN8oYAcYoaEXbqqbStTBOy8E4qG0FGsSabM67ufduit0xzikswO7fvbu4N3CWRxR_QmxQgg</recordid><startdate>20070501</startdate><enddate>20070501</enddate><creator>Grozovsky, R.</creator><creator>Morales, M.M.</creator><creator>Carvalho, D.P.</creator><general>Associação Brasileira de Divulgação Científica</general><scope>GPN</scope></search><sort><creationdate>20070501</creationdate><title>Biphasic modulation of insulin receptor substrate-1 during goitrogenesis</title><author>Grozovsky, R. ; Morales, M.M. ; Carvalho, D.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-s243t-cb086b93b2159e12a3d4be2d74631a79bb30bb908388975a63bea4fbe06d50a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>BIOLOGY</topic><topic>MEDICINE, RESEARCH & EXPERIMENTAL</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grozovsky, R.</creatorcontrib><creatorcontrib>Morales, M.M.</creatorcontrib><creatorcontrib>Carvalho, D.P.</creatorcontrib><collection>SciELO</collection><jtitle>Brazilian journal of medical and biological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grozovsky, R.</au><au>Morales, M.M.</au><au>Carvalho, D.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biphasic modulation of insulin receptor substrate-1 during goitrogenesis</atitle><jtitle>Brazilian journal of medical and biological research</jtitle><addtitle>Braz J Med Biol Res</addtitle><date>2007-05-01</date><risdate>2007</risdate><volume>40</volume><issue>5</issue><spage>679</spage><epage>686</epage><pages>679-686</pages><issn>1414-431X</issn><abstract>Insulin receptor substrate-1 (IRS-1) is the main intracellular substrate for both insulin and insulin-like growth factor I (IGF-I) receptors and is critical for cell mitogenesis. Thyrotropin is able to induce thyroid cell proliferation through the cyclic AMP intracellular cascade; however, the presence of either insulin or IGF-I is required for the mitogenic effect of thyroid-stimulating hormone (TSH) to occur. The aim of the present study was to determine whether thyroid IRS-1 content is modulated by TSH in vivo. Strikingly, hypothyroid goitrous rats, which have chronically high serum TSH levels (control, C = 2.31 ± 0.28; methimazole (MMI) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated with 0.03% MMI in drinking water for 21 days, showed significantly reduced thyroid IRS-1 mRNA content. Since goiter was already established in these animals by MMI for 21 days, we also evaluated IRS-1 expression during goitrogenesis. Animals treated with MMI for different periods of time showed a progressive increase in thyroid weight (C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MMI 10d = 33.8 ± 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.9 ± 3.92 mg, N = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; MMI 5d = 9.95 ± 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25.65 ± 1.23; MMI 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals per group). Thyroid IRS-1 mRNA expression increased progressively during goitrogenesis, being significantly higher by the 14th day of MMI treatment, and then started to decline, reaching the lowest values by the 21st day, when a significant reduction was detected. In the liver of these animals, however, a significant decrease of IRS-1 mRNA was detected after 14 days of MMI treatment, a mechanism probably involved in the insulin resistance that occurs in hypothyroidism. The increase in IRS-1 expression during goitrogenesis may represent an important event associated with the increased rate of cell mitosis promoted by TSH and indicates that insulin and IGF-I are important co-mitogenic factors in vivo, possibly acting through the activation of IRS-1.</abstract><pub>Associação Brasileira de Divulgação Científica</pub><doi>10.1590/S0100-879X2006005000090</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1414-431X |
ispartof | Brazilian journal of medical and biological research, 2007-05, Vol.40 (5), p.679-686 |
issn | 1414-431X |
language | eng |
recordid | cdi_scielo_journals_S0100_879X2007000500011 |
source | IngentaConnect Journals; SciELO |
subjects | BIOLOGY MEDICINE, RESEARCH & EXPERIMENTAL |
title | Biphasic modulation of insulin receptor substrate-1 during goitrogenesis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T11%3A12%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-scielo&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biphasic%20modulation%20of%20insulin%20receptor%20substrate-1%20during%20goitrogenesis&rft.jtitle=Brazilian%20journal%20of%20medical%20and%20biological%20research&rft.au=Grozovsky,%20R.&rft.date=2007-05-01&rft.volume=40&rft.issue=5&rft.spage=679&rft.epage=686&rft.pages=679-686&rft.issn=1414-431X&rft_id=info:doi/10.1590/S0100-879X2006005000090&rft_dat=%3Cscielo%3ES0100_879X2007000500011%3C/scielo%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-s243t-cb086b93b2159e12a3d4be2d74631a79bb30bb908388975a63bea4fbe06d50a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_scielo_id=S0100_879X2007000500011&rfr_iscdi=true |